Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis
Introduction: The reactivation of CMV (Cytomegalovirus) in renal transplant recipients may be manifested across a clinical spectrum from asymptomatic viraemia to organ rejection. The purpose of this study is to evaluate the patients who have experienced CMV infection after renal transplantation in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2022-12-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/17218 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148299794808832 |
|---|---|
| author | Tugba Sari Belda Dursun Mevlut Ceri Cagri Ergin Huseyin Turgut Murat Ozban |
| author_facet | Tugba Sari Belda Dursun Mevlut Ceri Cagri Ergin Huseyin Turgut Murat Ozban |
| author_sort | Tugba Sari |
| collection | DOAJ |
| description |
Introduction: The reactivation of CMV (Cytomegalovirus) in renal transplant recipients may be manifested across a clinical spectrum from asymptomatic viraemia to organ rejection. The purpose of this study is to evaluate the patients who have experienced CMV infection after renal transplantation in the last twelve years, and to assess the efficacy of valacyclovir.
Methodology: Renal transplant recipients’ demographic, clinical and laboratory data were evaluated retrospectively between 2006-2018. Valaciclovir was given at the standard prophylaxis dose of 2000 mg/daily. CMV Polymerase Chain reaction (PCR) was performed in 2-week intervals until 1 year after transplantation, and upon any symptoms attributable to CMV.
Results: The entire study group had D+/R+ (donor–positive, recipient-positive) serological status of the CMV virus. 171 (59.2%) patients had only CMV infection, 60 (20.8%) had overall CMV antigen positivity until the end of the follow-up period and 7 (2.4%) patients had CMV disease. Rejection episodes were diagnosed in 31 (10.8%) patients; 20 (64.5%) of those were PCR positive for CMV; mortality rate was 12 (4.2%) but those who died had a non-CMV related disease.
Conclusions: Valaciclovir may be preferred in prophylaxis instead of valganciclovir as we used in our study since valganciclovir has prolonged treatment time, rapid development of drug resistance, drug toxicity and high cost.
|
| format | Article |
| id | doaj-art-2a3d2434c81e452c934d4fb81751c4e7 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-2a3d2434c81e452c934d4fb81751c4e72025-08-20T02:27:18ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802022-12-01161210.3855/jidc.17218Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxisTugba Sari0Belda Dursun1Mevlut Ceri2Cagri Ergin3Huseyin Turgut4Murat Ozban5Deparment of Infectious Diseases and Clinical Microbiology, Pamukkale University Faculty of Medicine, Denizli, TurkeyDepartment of Nephrology, Pamukkale University Faculty of Medicine, Denizli, TurkeyDepartment of Nephrology, Pamukkale University Faculty of Medicine, Denizli, TurkeyDeparment of Microbiology, Pamukkale University Faculty of Medicine, Denizli, TurkeyDeparment of Infectious Diseases and Clinical Microbiology, Pamukkale University Faculty of Medicine, Denizli, TurkeyDeparment of General Surgery, Pamukkale University Faculty of Medicine, Denizli, Turkey Introduction: The reactivation of CMV (Cytomegalovirus) in renal transplant recipients may be manifested across a clinical spectrum from asymptomatic viraemia to organ rejection. The purpose of this study is to evaluate the patients who have experienced CMV infection after renal transplantation in the last twelve years, and to assess the efficacy of valacyclovir. Methodology: Renal transplant recipients’ demographic, clinical and laboratory data were evaluated retrospectively between 2006-2018. Valaciclovir was given at the standard prophylaxis dose of 2000 mg/daily. CMV Polymerase Chain reaction (PCR) was performed in 2-week intervals until 1 year after transplantation, and upon any symptoms attributable to CMV. Results: The entire study group had D+/R+ (donor–positive, recipient-positive) serological status of the CMV virus. 171 (59.2%) patients had only CMV infection, 60 (20.8%) had overall CMV antigen positivity until the end of the follow-up period and 7 (2.4%) patients had CMV disease. Rejection episodes were diagnosed in 31 (10.8%) patients; 20 (64.5%) of those were PCR positive for CMV; mortality rate was 12 (4.2%) but those who died had a non-CMV related disease. Conclusions: Valaciclovir may be preferred in prophylaxis instead of valganciclovir as we used in our study since valganciclovir has prolonged treatment time, rapid development of drug resistance, drug toxicity and high cost. https://jidc.org/index.php/journal/article/view/17218Renal transplantationCMVCMV diseaseValacyclovir |
| spellingShingle | Tugba Sari Belda Dursun Mevlut Ceri Cagri Ergin Huseyin Turgut Murat Ozban Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis Journal of Infection in Developing Countries Renal transplantation CMV CMV disease Valacyclovir |
| title | Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis |
| title_full | Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis |
| title_fullStr | Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis |
| title_full_unstemmed | Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis |
| title_short | Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis |
| title_sort | evaluation of cytomegalovirus infection disease in igg positive renal transplantation recipients on valaciclovir prophylaxis |
| topic | Renal transplantation CMV CMV disease Valacyclovir |
| url | https://jidc.org/index.php/journal/article/view/17218 |
| work_keys_str_mv | AT tugbasari evaluationofcytomegalovirusinfectiondiseaseiniggpositiverenaltransplantationrecipientsonvalaciclovirprophylaxis AT beldadursun evaluationofcytomegalovirusinfectiondiseaseiniggpositiverenaltransplantationrecipientsonvalaciclovirprophylaxis AT mevlutceri evaluationofcytomegalovirusinfectiondiseaseiniggpositiverenaltransplantationrecipientsonvalaciclovirprophylaxis AT cagriergin evaluationofcytomegalovirusinfectiondiseaseiniggpositiverenaltransplantationrecipientsonvalaciclovirprophylaxis AT huseyinturgut evaluationofcytomegalovirusinfectiondiseaseiniggpositiverenaltransplantationrecipientsonvalaciclovirprophylaxis AT muratozban evaluationofcytomegalovirusinfectiondiseaseiniggpositiverenaltransplantationrecipientsonvalaciclovirprophylaxis |